Diagnosis scoring for clinical identification of children with heterozygous familial hypercholesterolemia

Journal of Pediatric Gastroenterology and Nutrition

Volumn 48, Issue 4, 2009, Pages 456-463

  Benlian, Pascale ^a   Turquet, Anne ^b   Carrat, Fabrice ^a   Amsellem, Sabine ^a   Sanchez, Lydie ^b   Briffaut, Dorothée ^b   Girardet, Jean Philippe ^b,c  

^a HÔPITAL SAINT ANTOINE   (France)

^b SERVICE DE DERMATOLOGIE   (France)

^c ARMAND TROUSSEAU HOSPITAL   (France)

Author keywords

Genetics; Hyperlipidemia; Low density lipoprotein; Lowdensity lipoprotein receptor mutation; Risk factors

Indexed keywords

APOLIPOPROTEIN B; APOLIPOPROTEIN E; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; PROPROTEIN CONVERTASE 1; SUBTILISIN;

ARTICLE; CHILD; CLINICAL ASSESSMENT; CLINICAL PROTOCOL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; FALSE NEGATIVE RESULT; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; GENE LOCUS; GENE MUTATION; GENETIC ANALYSIS; GENOTYPE; HETEROZYGOSITY; HETEROZYGOTE; HUMAN; LOW FAT DIET; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; NUCLEOTIDE SEQUENCE; PRESCHOOL CHILD; PRIORITY JOURNAL; QUESTIONNAIRE; SCHOOL CHILD; SCORING SYSTEM;

ADULT; ANTICHOLESTEREMIC AGENTS; CHILD; CHILD, PRESCHOOL; CHOLESTEROL, LDL; DIET, FAT-RESTRICTED; FEMALE; HETEROZYGOTE; HUMANS; HYPERCHOLESTEROLEMIA; LOGISTIC MODELS; MALE; PARENTS; RECEPTORS, LDL; REPRODUCIBILITY OF RESULTS; ROC CURVE;

EID: 67651015246     PISSN: 02772116     EISSN: None     Source Type: Journal    
DOI: 10.1097/MPG.0b013e3181810b30     Document Type: Article

References (36)

1. McCrindle BW, Urbina EM, Dennison BA, et al. Drug therapy of high-risk lipid abnormalities in children and adolescents: a scientific statement from the American Heart Association Atherosclerosis, Hypertension, and Obesity in Youth Committee, Council of Cardiovascular Disease in the Young, with the Council on Cardiovascular Nursing. Circulation 2007;115:1948-67.
2. Scientific Steering Committee on Behalf of the Simon Broome Register Group. Mortality in treated heterozygous familial hyperch-olesterolemia: implication for clinical management. Atherosclerosis 1999;142:105-12.
3. Goldstein JL, Hobbs HH, Brown MS. Familial hypercholesterole-mia. In: Scriver CR, Beaudet AL, Sly WS et al. (eds). The Metabolic and Molecular Basis of Inherited Diseases. New York: McGraw-Hill; 2001. pp. 2863-913.
4. Austin MA, Hutter CM, Zimmern RL, et al. Genetic causes of monogenic heterozygous familial hypercholesterolemia: a HuGE prevalence review. Am J Epidemiol 2004;160:407-20.
5. Torres AL, Moorjani S, Vohl MC, et al. Heterozygous familial hypercholesterolemia in children: low-density lipoprotein receptor mutational analysis and variation in the expression of plasma lipo-protein-lipid concentrations. Atherosclerosis 1996;126:163-71.
6. Wiegman A, Sijbrands EJ, Rodenburg J, et al. The apolipoprotein epsilon4 allele confers additional risk in children with familial hypercholesterolemia. Pediatr Res 2003;53:1008-12.
7. Tonstad S, Joakimsen O, Stensland-Bugge E, et al. Risk factors related to carotid intima-media thickness and plaque in children with familial hypercholesterolemia and control subjects. Arterioscler Thromb Vasc Biol 1996;16:984-91.
8. Aggoun Y, Bonnet D, Sidi D, et al. Arterial mechanical changes in children with familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 2000;20:2070-5.
9. de Jongh S, Lilien MR, op't Roodt J, et al. Early statin therapy restores endothelial function in children with familial hypercho-lesterolemia. J Am Coll Cardiol 2002;40:2117-21.
10. Wiegman A, Hutten BH, de Groot E, et al. Efficacy and safety of statin therapy in children with familial hypercholesterolemia. JAMA 2004;292:331-7.
11. van Aalst-Cohen ES, Jansen AC, Tanck MW, et al. Diagnosing familial hypercholesterolaemia: the relevance of genetic testing. Eur Heart J 2006;27:2240-6.
12. Scientific Steering Committee on Behalf of the Simon Broome Register Group. Risk of fatal coronary heart disease in familial hypercholesterolaemia. BMJ 1991;303:893-6.
13. Williams RR, Hunt SC, Schumacher MC, et al. Diagnosing heterozygous familial hypercholesterolemia using new practical criteria validated by molecular genetics. Am J Cardiol 1993;72:171-6.
14. World Health Organization Human Genetics DoNDP. Familial Hypercholesterolemia: Report of a Second WHO Consultation. Geneva: WHO; 1999.
15. Damgaard D, Larsen ML, Nissen PH, et al. The relationship of molecular genetic to clinical diagnosis of familial hypercholester-olemia in a Danish population. Atherosclerosis 2005;180:155-60.
16. Ose L, Tonstad S. The detection and management of dyslipidaemia in children and adolescents. Acta Paediatr 1995;84:1213-5.
17. Lambert D, Daubrosse E, Steinmetz J, et al. Valeurs de référence du cholestérol et des triacylglycerols plasmatiques et lipoprotéiniques chez des enfants sains. Arch Fr Pediatr 1984;41:145-50.
18. Rolland-Cachera MF, Cole TJ, Sempé M,etal. Body mass index variation: centiles from birthto87years. EurJ Clin Nutr 1991;45:13-21.
19. National Cholesterol Education Program. Report of the expert panel on blood cholesterol levels in children and adolescents. Pediatrics 1992;89:525-84.
20. ESPGAN Committee on Nutrition. Committee report: childhood diet and prevention of coronary heart disease. J Pediatr Gastroenterol Nutr 1994;19:161-9.
21. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low density lipoprotein cholesterol in plasma without use of the ultracentrifuge. Clin Chem 1972;18:499-502.
22. Amsellem S, Briffaut D, Carrié A, et al. Intronic mutations outside of Alu-repeat rich domains of the LDL receptor gene are a cause of familial hypercholesterolemia. Hum Genet 2002;111:501-10.
23. Allard D, Amsellem S, Abifadel M, et al. Novel mutations of the PCSK9 gene cause variable phenotype of autosomal dominant hypercholesterolemia. Hum Mutat 2005;26:497.
24. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1982; 143:29-36.
25. Steyerberg EW, Harrel FE Jr, Borsboom GJ, et al. Internal validation of predictive models: efficiency of some procedures for logistic regression analysis. J Clin Epidemiol 2001;54:774-81.
26. Civeira F. Guidelines for the diagnosis and management of heterozygous familial hypercholesterolemia. Atherosclerosis 2004; 173:55-68.
27. Berenson GS. Childhood risk factors predict adult risk associated with subclinical cardiovascular disease: the Bogalusa heart study. Am J Cardiol 2002;90:3L-7L.
28. Wiegman A, De Groot E, Hutten BA, et al. Arterial intima-media thickness in children heterozygous for familial hypercholesterole-mia. Lancet 2004;363:369-70.
29. Wiegman A, Rodenburg J, De Jongh S, et al. Family history and cardiovascular risk in familial hypercholesterolemia: data in more than 1000 children. Circulation 2003;107:1473-8.
30. Hadfield SG, Humphries SE. Implementation of cascade testing for the detection of familial hypercholesterolaemia. Curr Opin Lipidol 2005;16:428-33.
31. Widham K, Dirisamer A, Lindemayr A, et al. Diagnosis of families with familial hypercholesterolemia and/or ApoB-100 defect by means of DNA analysis of LDL-receptor gene mutations. J Inherit Metab Dis 2007;30:239-47.
32. Wald DS, Bestwick JP, Wald NJ. Child-parent screening for familial hypercholesterolaemia: screening strategy based on a meta-analy-sis. BMJ 2007;335:599-606.
33. Innerarity TL, Mahley RW, Weisgraber KH, et al. Familial defective apolipoprotein B-100: a mutation of apolipoprotein B that causes hypercholesterolemia. J Lipid Res 1990;31:1337-49.
34. Horton JD, Cohen JC, Hobbs HH. Molecular biology of PCSK9: its role in LDL metabolism. Trends Biochem Sci 2007;32:71-7.
35. Viola S, Benlian P, Morali A, et al. Apolipoprotein B Arg3500Gln mutation prevalence in children with known hypercholesterolemia: a French multicenter study. J Pediatr Gastroenterol Nutr 2001;33:122-6.
36. Knoblauch H, Muller Myhsok B, Busjahn A, et al. A cholesterol-lowering gene maps to chromosome 13q. Am J Hum Genet 2000;66:157-66.